Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company focused on rare diseases, with a portfolio concentrated in hematology (hemophilia, hereditary angioedema) and immunology. The company operates primarily in Europe and North America, generating revenue through proprietary therapies like Doptelet (thrombocytopenia), Gamifant (hemophagocytic lymphohistiocytosis), and partnered products including Alprolix and Elocta (hemophilia). Sobi's competitive position rests on its expertise in ultra-rare disease commercialization, established European infrastructure, and growing presence in immunology.
Sobi operates a specialized commercial model targeting ultra-rare diseases with high unmet need, allowing premium pricing ($200,000-$500,000+ annual treatment costs) due to limited competition and orphan drug designations. Revenue comes from direct sales to specialized treatment centers and hospitals in Europe (50-55% of sales) and North America (35-40%). The company maintains pricing power through regulatory exclusivity (orphan designations typically 7-10 years), patent protection, and high switching costs given physician expertise requirements. Gross margins of 43.6% reflect manufacturing complexity for biologics and royalty payments to partners (Biogen for hemophilia products). The business benefits from recurring revenue as rare disease patients require lifelong therapy, creating predictable cash flows once market penetration is achieved.
Doptelet revenue trajectory and market share gains in thrombocytopenia, particularly US penetration versus Promacta/Nplate
Hemophilia franchise stability amid gene therapy competitive threats (BioMarin's Roctavian, Pfizer's hemophilia B gene therapy)
Pipeline readouts for SEL-212 (chronic refractory gout) and other late-stage assets, including regulatory approval timelines
European pricing and reimbursement decisions, particularly in Germany, France, and UK where government negotiations impact realized prices
Business development activity including in-licensing deals or acquisitions to expand rare disease portfolio
Gene therapy disruption in hemophilia: One-time curative treatments from BioMarin, Pfizer, and others could eliminate chronic therapy need for hemophilia patients, threatening 30-40% of Sobi's revenue base over 5-10 year horizon
European pricing pressure: Government healthcare systems increasingly demanding price cuts or outcome-based contracts for specialty drugs, with recent examples showing 15-25% price reductions in major markets
Regulatory pathway complexity: Ultra-rare disease approvals based on small trial populations face increasing scrutiny from FDA/EMA, potentially delaying or preventing pipeline asset approvals
Hemophilia market share erosion to Sanofi's Cablivi, Takeda's portfolio, and emerging extended half-life products with superior dosing convenience
Doptelet competition from Amgen's Nplate and Novartis' Promacta/Revolade, which have established market positions and physician familiarity
Pipeline execution risk with SEL-212 facing competitive chronic gout market with entrenched generics and Horizon's Krystexxa
Current ratio of 0.90 indicates tight working capital management, potentially limiting financial flexibility for opportunistic M&A or pipeline investments without accessing capital markets
Net margin compression to 1.7% (down from historical 8-12%) and 87.7% net income decline suggests recent one-time charges, restructuring costs, or royalty/milestone payments that warrant monitoring for sustainability
Royalty obligations to Biogen on hemophilia products (estimated 20-30% of product sales) create fixed payment requirements that pressure margins if sales decline
low - Rare disease treatments are medically necessary with limited substitutes, making demand highly inelastic to economic conditions. Patients with hemophilia, hereditary angioedema, or hemophagocytic lymphohistiocytosis require continuous therapy regardless of GDP growth. However, government healthcare budget pressures during recessions can lead to more aggressive pricing negotiations in Europe, potentially compressing realized prices by 5-10%. The 8.2% revenue growth reflects underlying patient population expansion and new product launches rather than economic sensitivity.
Rising rates create moderate valuation pressure as biotech stocks typically trade on long-duration cash flows (products have 10-15 year commercial lifecycles). Higher discount rates compress NPV of pipeline assets and future revenue streams, particularly impacting the P/S multiple which sits at 5.0x. However, Sobi's strong operating cash flow of $8.5B (66.5% FCF yield) and low leverage (0.31 D/E) insulate the business from financing cost pressures. The company is not dependent on capital markets access for operations, unlike earlier-stage biotechs.
Minimal - Sobi's customer base consists primarily of hospitals and specialized treatment centers with government or private insurance reimbursement, resulting in low bad debt risk. The current ratio of 0.90 suggests working capital management focus, but rare disease reimbursement is generally reliable once approved. Credit market conditions have limited direct impact on operations, though tighter credit could affect M&A financing for portfolio expansion.
value with growth optionality - The 66.5% FCF yield and 5.0x P/S multiple suggest the market is pricing in significant hemophilia franchise risk from gene therapy, creating value opportunity if core business proves more durable. Growth investors focus on Doptelet's $500M+ peak sales potential and pipeline optionality. The 21.4% one-year return reflects re-rating as gene therapy competitive fears moderated. Rare disease specialists and European healthcare investors are core holders given geographic concentration.
moderate-to-high - Biotech stocks typically exhibit 25-35% annualized volatility driven by binary clinical/regulatory events, competitive developments, and pricing policy changes. The 27.7% six-month return demonstrates momentum potential on positive catalysts. Limited analyst coverage for European mid-cap biotechs can amplify price swings on news flow. Beta likely 1.2-1.4x relative to broader healthcare sector.
